TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.
| Revenue (Most Recent Fiscal Year) | $616.29M |
| Net Income (Most Recent Fiscal Year) | $447.18M |
| PE Ratio (Current Year Earnings Estimate) | 30.41 |
| PE Ratio (Trailing 12 Months) | 13.66 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.69 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 14.19 |
| Pre-Tax Margin (Trailing 12 Months) | 17.46% |
| Net Margin (Trailing 12 Months) | 65.95% |
| Return on Equity (Trailing 12 Months) | 88.73% |
| Return on Assets (Trailing 12 Months) | 43.44% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.28 |
| Inventory Turnover (Trailing 12 Months) | 0.85 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $2.77 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.86 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 153.08M |
| Free Float | 136.80M |
| Market Capitalization | $6.09B |
| Average Volume (Last 20 Days) | 2.27M |
| Beta (Past 60 Months) | 1.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.64% |
| Percentage Held By Institutions (Latest 13F Reports) | 58.58% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |